Combined therapy for thyroid squamous cell carcinoma.
BACKGROUND.: Squamous carcinoma of the thyroid is a rare aggressive disease, resulting in poor prognosis. METHODS AND RESULTS.: We combined cisplatin with paclitaxel on a weekly basis as induction therapy, achieving a high cumulative dose, in a patient with squamous cell tumor of the thyroid with arterial encasement. After surgery, pathologic examination confirmed a complete resection of the primary tumor with clear margins, revealing a successful induction treatment with chemotherapy. CONCLUSIONS.: Our patient now has a recurrence-free survival of >20 months, longer than the mean survival described in the literature.
De Vos
Filip Yves F L
FY
Department of Internal Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands. f.devos@erasmusmc.nl
Sewnaik
Aniel
A
de Wilt
J Hans W
JH
Smid
Ernst J
EJ
den Bakker
Michael A
MA
van Meerten
Esther
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000601:surgery
D017239:Paclitaxel; D002945:Cisplatin